Vitamin D: Deficiency, Diversity and Dosage

Journal of Orthomolecular Medicine

Volumn 18, Issue 3-4, 2003, Pages 194-204

  Saul, Andrew W ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; HEPARIN; ISONIAZID; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; TUBERCULOSTATIC AGENT; VITAMIN D;

COLON CANCER; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; ENTERITIS; HEART DILATATION; HEART DISEASE; HUMAN; HYPERTENSION; LUPUS VULGARIS; MULTIPLE SCLEROSIS; NUTRITIONAL REQUIREMENT; OBESITY; OSTEOPOROSIS; PSORIASIS; REVIEW; RICKETS; SCLERODERMA; SECONDARY HYPERPARATHYROIDISM; SUN EXPOSURE; VITAMIN D DEFICIENCY; VITAMIN D INTOXICATION; VITAMIN SUPPLEMENTATION;

EID: 0142054068     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Freinkel S: The Healing Vitamin. Reader's Digest. June, 2003.
2. http://www.ibl-hamburg.com/prod/mg_11021_ m.htm
3. Int J Circumpolar Health, 2000; 59:26-32.
4. http://www.cyberlipid.org/vitd/vitd0001.htm
5. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R: Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr, Vol 68, 854-858, 1998.
6. http://www.vitamer.com/faq_ts_pygeum.html
7. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, Chapter 7. 1999; National Academies Press, Washington, DC.
8. Vieth R, Chan PC, MacFarlane GD: Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr, 2001; Feb; 73(2):288-94.
9. http://www.emedicine.com/emerg/topic638.htm
10. The Merck Manual of Diagnosis and Therapy. Section 1. Chapter 3. Vitamin Deficiency, Dependency, And Toxicity. Vitamin D Toxicity. http://www.merck.com/pubs/mmanual/section1/chapter3/3e.htm
11. Williams SR: Nutrition and Diet Therapy, 6th edition. St. Louis: Mosby, 1989. 220-221.
12. Northwestern University, Feinberg School of Medicine. Nutrition Fact Sheet: Vitamin D. http://www.feinberg.northwestern.edu/nutrition/factsheets/vitamin-d.html
13. Bicknell F, Prescott F: The Vitamins in Medicine, 3rd edition. Milwaukee, WI: Lee Foundation. p 544 and 578-591.1953.
14. Marya RK, Rathee S, Lata V et al. Effects of vitamin D supplementation in pregnancy. Gynecol Obstet Invest, 1981; 12:155-161.
15. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ; 2003; Mar 1; 326 (7387):469.
16. Glerup H, Mikkelsen K, Poulsen L, et al: Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med, 2000; 247:260-268.
17. Eguchi M and Kaibara N: Treatment of hypophosphataemic vitamin D-resistant rickets and adult presenting hypophosphataemic vitamin D-resistant osteomalacia. Int Orthop, 1980; 3:257-264.
18. Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr, 1999; May; 69(5):842-56.
19. Garrison RH Jr, Somer E: The Nutrition Desk Reference, 2nd Edition. New Canaan, CT: Keats, 1990.
20. Cholecalciferol (Vitamin D3) Chemical Profile 12/84. US Environmental Protection Agency, Washington, DC. Chemical Fact Sheet Number 42. December 1, 1984. http://pmep.cce.cornell. edu/profiles/rodent/cholecalciferol/rod-prof-cholecalciferol.html
21. Woodhead JS, Ghose RR, Gupta SK: Severe hypophosphataemic osteomalacia with primary hyperparathyroidism. Br Med J, 1980; 281:647-648.
22. Gordon CM et al: In press. http://www.philly. com/mld/philly/living/health/6119306.htm
23. BluePrint for Health Herb Index: Vitamin D. Blue Cross and Blue Shield of Minnesota, Inc. 2002. http://blueprint.bluecrossmn.com/topic/ topic100587894
24. Willis M, Fairly A: Effect of increased dietary phytic acid on cholecalciferol requirements in rats. Lancet, 1972; v. 7774:406.
25. McCormick CC: Passive diffusion does not play a major role in the absorption of dietary calcium in normal adults. J Nutr, 2002; Nov; 132(11):3428-30.
26. Dawson-Hughes B, Harris SS, Krall EA, et al: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 1997; 337:670-676.
27. Mitric JM: Maturity News Service, November 15, 1992.
28. Recker RR: Osteoporosis. Contemp Nutr, 1983; 8/5.
29. Christiansen C, Rodbro P: Initial and maintenance doses of vitamin D2 in the treatment of anticonvulsant osteomalacia. Acta Neurol Scand, 1974; 50:631-641.
30. Yeste D, Carrascosa A: Nutritional rickets in childhood: analysis of 62 cases. Med Clin, (Barcel). 2003; Jun 7/121(1):23-7.
31. Anatoliotaki M, Tsilimigaki A, Tsekoura T, Schinaki A, Stefanaki S, Nikolaidou P: Congenital rickets due to maternal vitamin D deficiency in a sunny island of Greece. Acta Paediatr. 2003; 92(3):389-91.
32. Hoecker CC, Kanegaye JT: First place winner. Recurrent febrile seizures: an unusual presentation of nutritional rickets. J Emerg Med, 2002; Nov; 23(4):367-70.
33. Johnson GH, Willis F: Seizures as the presenting feature of rickets in an infant. Med J Aust 2003; May 5; 178(9):467.
34. Stebbing C, Mansy S, Kanabar D: The first reported presentation of rickets with metabolic seizures. Hosp Med, Nov 63(11):690-1.
35. Shah M, Salhab N, Patterson D, et al: Nutritional rickets still afflict children in north Texas. Tex Med. 2000; 96:64-68.
36. Kreiter SR, Schwartz RP, Kirkman HN et al: Nutritional rickets in African American breast-fed infants. J Pediatr, 2000; Aug; 137(2):153-7.
37. Lee JR: Fluoridation and osteoporosis. Natl Fluoridation News, 1986-7; 32:1,2.
38. Medical World News, October 23, 1989 and November 13, 1989. JAMA, July 25, 1990, June 19, 1991 and July 24, 1991; Am J Epidemiol, April 15, 1991; and the Am J Publ Health, July, 1990.
39. Medical World News, October 23, 1989 and November 13, 1989. JAMA, July 25, 1990, June 19, 1991 and July 24, 1991; Am J Epidemiol, April 15, 1991; and the Am J Publ Health, July, 1990.
40. Medical World News, October 23, 1989 and November 13, 1989. JAMA, July 25, 1990, June 19, 1991 and July 24, 1991; Am J Epidemiol, April 15, 1991; and the Am J Publ Health, July, 1990.
41. Medical World News, October 23, 1989 and November 13, 1989. JAMA, July 25, 1990, June 19, 1991 and July 24, 1991; Am J Epidemiol, April 15, 1991; and the Am J Publ Health, July, 1990.
42. Review of fluoride benefits and risks. U.S. Public Health Service, February, 1991.
43. Fluoridation of Water. Chemical and Engineering News, 1988; 66/Aug 1:26-42.
44. Wortsman J et al: Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr, 2000; 72: 690-693.
45. Holick MF: Vitamin D: A millenium perspective. J Cell Biochem, 2003; 88:296-307.
46. Key SW, Marble M: Studies link sun exposure to protection against cancer. Cancer Weekly Plus. 1997; Nov 17:5-6.
47. Studzinski GP, Moore DC: Sunlight: can it prevent as well as cause cancer? Cancer Res. 1995; 55:4014-4022.
48. Sullivan K: Naked at noon: Understanding sunlight and vitamin D. North Bergen, NJ: Basic Health Publications. In press. http://www. sunlightd.org
49. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V, Lindsay R: Fracture history and bone loss in patients with MS. Neurology, 1998; Oct; 51(4):1161-5.
50. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R: High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology, 1994; Sep; 44(9):1687-92.
51. Hayes CE, Cantorna MT, DeLuca HF: Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med, 1997; Oct; 216(1):21-27.
52. Hayes CE: Vitamin D: a natural inhibitor of multiple sclerosis. Proc Nutr Soc, Nov; 2000; 59(4):531-5.
53. Embry AF: Vitamin D supplementation in the fight against multiple sclerosis. http:// www.direct-ms.org/vitamind.html
54. Goldberg P: Multiple Sclerosis: vitamin D and calcium as environmental determinants of prevalence. Part 1: Sunlight, dietary factors and epidemiology. Intl J Environ Studies, 1974; 19-27.
55. Goldberg P: Multiple Sclerosis: vitamin D and calcium as environmental determinants of prevalence. Part 2: Biochemical and genetic factors. Intl J Environ Studies, 1974; 6:121-129.
56. Lemire J, Archer D: 1,25-dehydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest; 1991: 87:1103-1107.
57. Cantorna M, Hayes C and DeLuca H: 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad. Sci, 1996; 93:7861-7864.
58. Goldberg P, Fleming M, Picard E: Multiple Sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypoth, 1986; 21:193-200.
59. Smith LH: Clinical Guide to the Use of Vitamin C. Portland, OR: Life Sciences Press, 1988; 42-53.
60. Klenner FR: Treating Multiple Sclerosis Nutritionally," Cancer Control J, undated; 2:3:16-20.
61. Klenner FR: Response of peripheral and central nerve pathology to mega-doses of the vitamin B-complex and other metabolites. J Appl Nutr, 1973; 3.
62. Scragg R: Sunlight, vitamin D, and cardiovascular disease. In: Crass MF II, Avioli LV, eds. Calcium Regulating Hormones and Cardiovascular Function. Boca Raton, Fla: CRC Press; 213-237. 1995.
63. O'Connell TD, Simpson RU: 1,25-dihydroxy vitamin D3 and cardiac muscle structure and function. In: Crass MF II, Avioli LV, eds. Calcium-Regulating Hormones and Cardiovascular Function. Boca Raton, Fla: CRC Press; 191-211. 1995.
64. Barthel HR, Scharla SH: Benefits beyond the bones-vitamin D against falls, cancer, hypertension and autoimmune diseases. Dtsch Med Wochenschr. 2003; 2/28,128(9):440-6.
65. Rostand SG: Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension, 1997; 30(2 pt 1):150-156.
66. Werbach MR and Moss J: Textbook of Nutritional Medicine. Tarzana, Calif: Third Line Press; 1999. 423.
67. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol, 2003; Jan 1; 41(1):105-12.
68. Nishio K, Mukae S, Aoki S et al: Congestive heart failure is associated with the rate of bone loss. J Intern Med, 2003; Apr; 253(4):439-46.
69. Price DI, Stanford LC, Braden DS, Ebeid MR, Smith JC. Hypocalcemic Rickets: An Unusual Cause of Dilated Cardiomyopathy. Pediatr Cardiol, 2003; Jun 6.
70. Humbert P, Dupond JL, Agache P et al: Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol, 1993; 73(6):449-451.
71. Morimoto S, Yoshikawa K, Kozuka T et al: An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol, 1986; 115(4):421-429.
72. Cantorna MT, Munsick C, Bemiss C, Mahon BD: 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr, 2000; Nov; 130(11):2648-52.
73. Bicknell F, Prescott F: The Vitamins in Medicine, 3rd edition. Milwaukee, WI: Lee Foundation. 1953; 573.
74. Martinez ME, Giovannucci EL, Colditz GA, et al: Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst. 1996; 88:1375-1382.
75. Kearney J, Giovannucci E, Rimm EB, et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol, 1996; 143:907-917.
76. Tong WM, Kallay E, Hofer H, et al: Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer, 1998; 34: 2119-2125.
77. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P: Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology, 2002; 63(2):151-7.
78. Thys-Jacobs S, Donovan D, Papadopoulos A, et al: Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids, 1999; 64:430-435.
79. Cantorna M, Hayes C and DeLuca H. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr, 1998; 128:68-72.
80. Lemire J, Ince A, Takashima M: 1,25-dihydroxy vitamin D3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity, 1992; 12:143-148.
81. Mathieu C et al: Prevention of autoimmune diabetes in NOD mice by dihydroxyvitamin D3. Diabetology, 1994; 37:552-558.
82. Hypponen E, Laara E, Reunanen A, et al: Intake of vitamin D and risk of type I diabetes: a birth-cohort study. Lancet, 2001; 358:1500-1503.
83. Stene LC, Ulriksen J, Magnus P, et al: Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia, 2000; 43:1093-1098.
84. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia, 1999; 42:51-54.
85. Tarpey v. Crescent Ridge Dairy, Inc., 47 Mass. App. Ct 380.
86. http://www.dwpm.com/content/main/ litigation00_news.php3
87. Martini FH: Hypervitaminosis. Anatomy and Physiology, Chapter 25: Metabolism and Energetics. NY: Prentice Hall, 2000.